Publication

Article

CURE

Kidney Cancer Special Issue 2022
Volume

Running the Race of Cancer

Going through cancer is a marathon, not a sprint.

"It's a marathon, not a sprint” is a common phrase that applies to many challenges in life, particularly to patients who’ve been diagnosed with cancer.

Their race is a long one, riddled with ups and downs, whether it be at diagnosis, throughout treatment, after treatment or even during survivorship. A patient with kidney cancer who receives treatment with newer agents such as immunotherapy drugs and tyrosine kinase inhibitors, for example, may experience side effects as the therapy effectively reduces tumor size — and may become nervous about the possibility of their treatment dose being lowered or even stopped. However, findings from clinical trials have demonstrated that dose reductions or even stopping treatment until side effects are resolved may still result in effective treatment of the disease.

In this special issue of CURE®, we spoke with two patients treated with tyrosine kinase inhibitors and immunotherapies for kidney cancer who experienced side effects during treatment. These side effects included high blood pressure, an underactive thyroid and elevated liver enzymes, all of which were managed with medications. And they continued to respond to their treatments despite these challenges.

We also spoke with two other patients with renal cell carcinoma and von Hippel-Lindau disease who have benefited from treatment with targeted drugs called hypoxia-inducible factor-2 alpha inhibitors, which represent a novel approach for treating these kidney cancers.

Also in this issue, an expert discusses how the treatment of sarcomatoid renal cell carcinoma has vastly changed during the past few years with the Food
and Drug Administration’s approval of immunotherapies. We also spoke with a pediatric oncologist to learn more about how the treatment of Wilms tumor has evolved the past 20 years, as part of our 20th anniversary content series.

Other topics addressed in this special issue include different surgical options for kidney cancer, what we can learn from “failed” clinical trials and the importance of becoming an active participant in one’s care.

As always, we hope you find our stories inspirational and informative. Thank you for reading.

MIKE HENNESSY JR.

President & CEO

MJH LIFE SCIENCES®


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Image of a man wearing a black suit and tie.
Related Content